Zimp7 Inhibitors
Zimp7 inhibitors belong to a distinct chemical class that plays a crucial role in modulating cellular processes by targeting the Zimp7 protein. Zimp7, short for zinc finger-containing insulin-responsive aminopeptidase 7, is a member of the aminopeptidase family and is characterized by the presence of zinc finger domains. These inhibitors are designed to specifically bind to the catalytic site of Zimp7, thereby regulating its enzymatic activity. The structural features of Zimp7 inhibitors are meticulously crafted to interact with the protein's active site, disrupting its normal function.
The mechanism of action of Zimp7 inhibitors involves interference with the aminopeptidase activity of the Zimp7 protein, which is known to be involved in various cellular processes. By modulating the enzymatic function of Zimp7, these inhibitors can potentially influence peptide metabolism and processing within cells. The chemical structure of Zimp7 inhibitors is optimized to enhance their binding affinity to the target protein, ensuring a precise and selective inhibition. Understanding the molecular interactions between these inhibitors and Zimp7 provides valuable insights into the intricate regulatory networks governing cellular functions. Further research into the detailed structural aspects and functional consequences of Zimp7 inhibition is essential for unraveling the broader implications of targeting this specific class of enzymes in cellular contexts.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 is a small molecule inhibitor of NEDD8-activating enzyme (NAE). Zimp7 is involved in SUMOylation processes which are related to NEDDylation pathways. Inhibition of NAE by MLN4924 can disrupt the NEDDylation cycle, potentially leading to an indirect decrease in SUMOylation and subsequent inhibition of Zimp7 function. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine is a medication known to increase the pH in intracellular vesicles. Zimp7 functions within the nuclear compartment and is dependent on correct protein trafficking. By altering vesicular pH, Chloroquine can indirectly affect the trafficking and localization of Zimp7, inhibiting its functional activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. Given that Zimp7 is a protein that could be subject to proteasomal degradation, the inhibition of the proteasome may lead to an accumulation of misfolded or damaged Zimp7, thereby indirectly inhibiting its functional activity through proteotoxic stress. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor similar to Bortezomib. By inhibiting the proteasome, Lactacystin can lead to an indirect inhibition of Zimp7 by promoting the accumulation of proteins tagged for degradation, including potentially misfolded or ubiquitinated Zimp7. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, which can influence the MAPK/ERK pathway. Zimp7 could be indirectly affected by alterations in the MAPK/ERK signaling, which is involved in a multitude of cellular processes, including those relating to the regulation of nuclear proteins like Zimp7. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, and by inhibiting PI3K, it affects the AKT signaling pathway. Since Zimp7 is a nuclear protein that may be regulated by pathways controlled by AKT signaling, its functional activity could be inhibited indirectly by LY294002. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The p38 MAPK pathway is involved in the stress response and could potentially regulate the activity or expression of nuclear proteins such as Zimp7. Inhibition of p38 MAPK could thus indirectly inhibit Zimp7 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream activators of ERK1/2 in the MAPK pathway. Since Zimp7 function could be modulated by MAPK signaling, U0126 can indirectly inhibit the functional activity of Zimp7 by dampening the MAPK pathway. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a reversible proteasome inhibitor that can prevent the degradation of ubiquitinated proteins. Zimp7 may be regulated by ubiquitin-mediated proteasomal degradation, and the use of MG132 could indirectly inhibit its function by stabilization of the protein, affecting its turnover. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. By inhibiting PI3K and subsequently AKT signaling, Zimp7’s functional activity could be indirectly inhibited due to the role of AKT in regulating nuclear protein functions. | ||||||